CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 2.27 and has seen 1,160,600 shares traded in the last trading session. The company, currently valued at $12.52 Billion, closed the last trade at $155.88 per share which meant it lost -$0.76 on the day or -0.49% during that session. The CRSP stock price is -41.26% off its 52-week high price of $220.2 and 50.79% above the 52-week low of $76.71. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.08 Million shares traded. The 3-month trading volume is 1.44 Million shares.
The consensus among analysts is that CRISPR Therapeutics AG (CRSP) is an Overweight stock at the moment, with a recommendation rating of 2.1. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 6 out of 21 have rated it as a Hold, with 14 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $3.52.
Despite being -0.49% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jun 30 when the CRSP stock price touched $169.76 or saw a rise of 8.18%. Year-to-date, CRISPR Therapeutics AG shares have moved 1.81%, while the 5-day performance has seen it change 9.37%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed 35.85%. Short interest in the company has seen 3.36 Million shares shorted with days to cover at 2.33.
Wall Street analysts have a consensus price target for the stock at $163.11, which means that the shares’ value could jump 4.64% from current levels. The projected low price target is $117 while the price target rests at a high of $220. In that case, then, we find that the current price level is +41.13% off the targeted high while a plunge would see the stock lose -24.94% from current levels.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Figures show that CRISPR Therapeutics AG shares have outperformed across the wider relevant industry. The company’s shares have gained +1.81% over the past 6 months, with this year growth rate of 112.48%, compared to 8.4% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 370.8% and 20.5% for the next quarter. Revenue growth from the last financial year stood is estimated to be +64633%.
15 analysts offering their estimates for the company have set an average revenue estimate of $420.92 Million for the current quarter. 15 have an estimated revenue figure of $61.05 Million for the next quarter concluding in September 01, 2021. Year-ago sales stood $18.12 Million and $148Million respectively for this quarter and the next, and analysts expect sales will grow by 2223% for the current quarter and 41150% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -52.5% over the past 5 years. Earnings growth for 2021 is a modest -550.5%.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 12.96% of the company shares, while shares held by institutions stand at 58.56% with a share float percentage of 67.28%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 576 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 8.29 Million shares worth more than $1.01 Billion. As of March 30, 2021, ARK Investment Management, LLC held 10.94% of shares outstanding.
The other major institutional holder is Capital International Investors, with the holding of over 4.87 Million shares as of March 30, 2021. The firm’s total holdings are worth over $593.25 Million and represent 6.43% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. As of May 30, 2021, the former fund manager holds about 6.46% shares in the company for having 4895771 shares of worth $578.58 Million while later fund manager owns 2.1 Million shares of worth $255.64 Million as of March 30, 2021, which makes it owner of about 2.77% of company’s outstanding stock.